FY2026 Earnings Forecast for ALDX Issued By HC Wainwright

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Stock analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for shares of Aldeyra Therapeutics in a note issued to investors on Wednesday, March 18th. HC Wainwright analyst M. Caufield now anticipates that the biotechnology company will post earnings of ($0.44) per share for the year, down from their prior forecast of ($0.15). HC Wainwright currently has a “Neutral” rating and a $2.00 target price on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q4 2026 earnings at ($0.02) EPS, FY2027 earnings at ($0.27) EPS, FY2028 earnings at $0.09 EPS, FY2029 earnings at $0.24 EPS and FY2030 earnings at $0.21 EPS.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03.

Separately, BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $5.50.

Aldeyra Therapeutics Price Performance

Shares of NASDAQ:ALDX opened at $1.81 on Friday. The company has a market capitalization of $108.93 million, a P/E ratio of -3.18 and a beta of 0.97. Aldeyra Therapeutics has a 1-year low of $1.07 and a 1-year high of $6.81. The firm’s 50 day simple moving average is $4.78 and its two-hundred day simple moving average is $5.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALDX. 683 Capital Management LLC grew its stake in Aldeyra Therapeutics by 126.9% during the second quarter. 683 Capital Management LLC now owns 1,080,000 shares of the biotechnology company’s stock valued at $4,136,000 after acquiring an additional 604,000 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Aldeyra Therapeutics in the 3rd quarter valued at $721,000. Panagora Asset Management Inc. lifted its stake in Aldeyra Therapeutics by 42.8% in the 2nd quarter. Panagora Asset Management Inc. now owns 72,059 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 21,605 shares in the last quarter. Intech Investment Management LLC lifted its stake in Aldeyra Therapeutics by 27.6% in the 2nd quarter. Intech Investment Management LLC now owns 29,983 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 6,477 shares in the last quarter. Finally, Capital Advisors Wealth Management LLC boosted its holdings in shares of Aldeyra Therapeutics by 46.3% during the 4th quarter. Capital Advisors Wealth Management LLC now owns 15,800 shares of the biotechnology company’s stock valued at $82,000 after purchasing an additional 5,000 shares during the last quarter. 59.71% of the stock is currently owned by institutional investors.

Insider Activity

In other Aldeyra Therapeutics news, Director Richard Douglas bought 70,000 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The stock was purchased at an average price of $1.40 per share, for a total transaction of $98,000.00. Following the completion of the transaction, the director owned 195,000 shares of the company’s stock, valued at $273,000. This trade represents a 56.00% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 9.60% of the company’s stock.

Key Stories Impacting Aldeyra Therapeutics

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Positive Sentiment: Insider buying: Director/insider Michael Alfieri increased his stake, purchasing 5,000 shares at ~$1.42 on March 18 — a modest signal of insider conviction that can be viewed as supportive amid the sell-off. SEC Filing: Insider Purchase
• Neutral Sentiment: Broker note status: HC Wainwright reaffirmed a Neutral rating and a $2.00 target while publishing updated model revisions. The Neutral stance limits upside endorsement from that shop but keeps coverage steady. HC Wainwright Reaffirms Neutral Rating
• Negative Sentiment: Analyst cuts: HC Wainwright sharply reduced EPS forecasts across 2026–2030 (Q4 2026 from $0.27 to ($0.02); FY2026 to ($0.44); FY2027 to ($0.27); FY2028–2030 also lowered). The revisions signal weaker expected profitability and push down research-driven valuation support. HC Wainwright Research Note
• Negative Sentiment: Lawsuits / investigations: Multiple law firms (Pomerantz; Levi & Korsinsky and others) have launched securities-fraud probes and class-action recruitment, alleging management misstatements around reproxalap’s efficacy and approval prospects. Litigation risk and potential disclosures raise investor uncertainty. Pomerantz Investigation Notice Levi & Korsinsky Alert
• Negative Sentiment: Market reaction / put buying: Heavy put-option activity and a multi-day slump (reports cite ~67% decline since Tuesday) indicate aggressive bearish positioning and rapid de-risking by traders following the FDA Complete Response Letter for reproxalap. That pressure has driven large volume and volatility. Put Options Flow Benzinga: What’s Going On
• Neutral Sentiment: Short-interest reports in recent feeds show inconsistent/zero values (likely data anomalies); treat reported short metrics cautiously until exchanges refresh official figures. No reliable signal from those entries.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.